[go: up one dir, main page]

UA118286C2 - Білок агоніст рецептора trail - Google Patents

Білок агоніст рецептора trail

Info

Publication number
UA118286C2
UA118286C2 UAA201611802A UAA201611802A UA118286C2 UA 118286 C2 UA118286 C2 UA 118286C2 UA A201611802 A UAA201611802 A UA A201611802A UA A201611802 A UAA201611802 A UA A201611802A UA 118286 C2 UA118286 C2 UA 118286C2
Authority
UA
Ukraine
Prior art keywords
receptor agonist
trail receptor
trail
agonist protein
agonist proteins
Prior art date
Application number
UAA201611802A
Other languages
English (en)
Inventor
Олівер Гіл
Кристіан Ґіферс
Майнольф Тіман
Фриц Ґ. Б'юканан
Дарен К. Філіпс
Сьюзан Е. Леп
Original Assignee
Еббві Інк.
Апоґенікс Аґ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еббві Інк., Апоґенікс Аґ filed Critical Еббві Інк.
Publication of UA118286C2 publication Critical patent/UA118286C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

Винахід належить до специфічного білка-агоніста рецептора TRAIL, нуклеїнової кислоти, кодуючої його, і способу лікування пацієнта, що має TRAIL-асоційоване захворювання або розлад. Білок-агоніст рецептора TRAIL включає три розчинних домени TRAIL і Fc-фрагмент. Білок-агоніст рецептора TRAIL є по суті неагрегуючим і придатним для терапевтичного, діагностичного і/або дослідницького застосування.
UAA201611802A 2014-04-23 2015-04-23 Білок агоніст рецептора trail UA118286C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (1)

Publication Number Publication Date
UA118286C2 true UA118286C2 (uk) 2018-12-26

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611802A UA118286C2 (uk) 2014-04-23 2015-04-23 Білок агоніст рецептора trail

Country Status (38)

Country Link
US (5) US9908927B2 (uk)
EP (2) EP3366699A1 (uk)
JP (2) JP6523331B2 (uk)
KR (2) KR20190135546A (uk)
CN (2) CN111718424A (uk)
AR (1) AR100168A1 (uk)
AU (3) AU2015249649B2 (uk)
BR (1) BR112016024515B1 (uk)
CA (2) CA2946402C (uk)
CL (1) CL2016002683A1 (uk)
CR (1) CR20160516A (uk)
CY (1) CY1120281T1 (uk)
DK (1) DK3134430T3 (uk)
DO (1) DOP2016000284A (uk)
EC (1) ECSP16089579A (uk)
ES (1) ES2672368T3 (uk)
HR (1) HRP20180950T1 (uk)
HU (1) HUE038914T2 (uk)
IL (2) IL248244B (uk)
LT (1) LT3134430T (uk)
MA (2) MA39770A (uk)
MX (2) MX2016013858A (uk)
MY (1) MY181986A (uk)
NO (1) NO2776305T3 (uk)
PE (1) PE20170299A1 (uk)
PH (2) PH12020500377A1 (uk)
PL (1) PL3134430T3 (uk)
PT (1) PT3134430T (uk)
RS (1) RS57153B1 (uk)
RU (1) RU2699285C2 (uk)
SG (3) SG10202111785VA (uk)
SI (1) SI3134430T1 (uk)
SM (1) SMT201800286T1 (uk)
TR (1) TR201806912T4 (uk)
TW (2) TWI747178B (uk)
UA (1) UA118286C2 (uk)
UY (1) UY36095A (uk)
WO (1) WO2015164588A1 (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745801C2 (ru) * 2015-05-04 2021-04-01 Аподжиникс Аг Одноцепочечные белки-агонисты рецептора cd40
AU2016341402B2 (en) * 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins
EP3365361A1 (en) * 2015-10-23 2018-08-29 Apogenix AG Single-chain light receptor agonist proteins
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CN109153711B (zh) * 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
EP3430034A1 (en) * 2016-03-16 2019-01-23 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017283487A1 (en) * 2016-06-13 2018-11-22 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3664832B1 (en) * 2017-08-11 2023-10-18 The Board of Trustees of the University of Illinois Truncated guinea pig l-asparaginase variants and methods of use
TW202003553A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
TW202002952A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
WO2022248662A1 (en) 2021-05-28 2022-12-01 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226173A1 (en) 1999-10-07 2002-07-31 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) * 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
CA2597789A1 (en) 2005-04-15 2006-10-19 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP3321277B1 (en) 2007-07-10 2019-09-18 Apogenix AG Tnf superfamily collectin fusion proteins
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2310509B1 (en) * 2008-07-21 2015-01-21 Apogenix GmbH Tnfsf single chain molecules
MX2011002759A (es) * 2008-09-22 2011-07-28 Amgen Inc Metodo de tratamiento.
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
CN102369291A (zh) * 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
CA2785139A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
SG10201505470QA (en) 2010-04-13 2015-08-28 Medimmune Llc Trail r2-specific multimeric scaffolds
EP2793949B1 (en) * 2011-12-23 2018-08-22 Innate Pharma Enzymatic conjugation of antibodies
WO2014013039A1 (en) 2012-07-18 2014-01-23 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms

Also Published As

Publication number Publication date
MX2019013587A (es) 2020-01-13
AU2015249649A1 (en) 2016-11-10
PE20170299A1 (es) 2017-05-06
MY181986A (en) 2021-01-18
NZ725476A (en) 2023-09-29
ES2672368T3 (es) 2018-06-14
ECSP16089579A (es) 2018-05-31
DOP2016000284A (es) 2017-02-15
JP2019162114A (ja) 2019-09-26
PH12016502079B1 (en) 2016-12-19
KR20190135546A (ko) 2019-12-06
HRP20180950T1 (hr) 2018-08-10
US9908927B2 (en) 2018-03-06
RU2699285C2 (ru) 2019-09-04
MA39770A (fr) 2015-10-29
TW202024123A (zh) 2020-07-01
IL248244A0 (en) 2016-11-30
JP6714751B2 (ja) 2020-06-24
US20210040178A1 (en) 2021-02-11
IL272612A (en) 2020-03-31
PH12020500377A1 (en) 2022-11-14
DK3134430T3 (en) 2018-05-22
CA2946402C (en) 2023-02-28
SMT201800286T1 (it) 2018-07-17
CA3184067A1 (en) 2015-10-29
RS57153B1 (sr) 2018-07-31
MX2016013858A (es) 2017-08-02
TWI683825B (zh) 2020-02-01
AU2020202247A1 (en) 2020-04-23
MA45069A (fr) 2019-04-03
CA2946402A1 (en) 2015-10-29
BR112016024515A2 (pt) 2017-10-10
AU2018271369A1 (en) 2018-12-20
NO2776305T3 (uk) 2018-01-27
RU2016145608A (ru) 2018-05-28
HUE038914T2 (hu) 2018-12-28
KR102079919B1 (ko) 2020-02-24
PT3134430T (pt) 2018-04-20
JP6523331B2 (ja) 2019-05-29
EP3366699A1 (en) 2018-08-29
SG10201806465TA (en) 2018-08-30
JP2017513503A (ja) 2017-06-01
TWI747178B (zh) 2021-11-21
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
BR112016024515B1 (pt) 2020-03-31
SG10202111785VA (en) 2021-12-30
EP3134430A1 (en) 2017-03-01
CN106459221B (zh) 2020-09-01
US20250145688A1 (en) 2025-05-08
US20240174731A1 (en) 2024-05-30
TR201806912T4 (tr) 2018-06-21
CY1120281T1 (el) 2019-07-10
LT3134430T (lt) 2018-05-10
CL2016002683A1 (es) 2017-07-07
CN106459221A (zh) 2017-02-22
CR20160516A (es) 2017-05-10
IL248244B (en) 2020-03-31
PH12016502079A1 (en) 2016-12-19
US20180222962A1 (en) 2018-08-09
KR20170012257A (ko) 2017-02-02
US20150337027A1 (en) 2015-11-26
WO2015164588A1 (en) 2015-10-29
TW201620928A (zh) 2016-06-16
UY36095A (es) 2015-10-30
EP3134430B1 (en) 2018-03-21
SG11201608767XA (en) 2016-11-29
SI3134430T1 (en) 2018-05-31
PL3134430T3 (pl) 2018-08-31
AU2015249649B2 (en) 2018-10-04
RU2016145608A3 (uk) 2018-12-26
AR100168A1 (es) 2016-09-14

Similar Documents

Publication Publication Date Title
UA118286C2 (uk) Білок агоніст рецептора trail
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
EP3679071A4 (en) PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EP3630181A4 (en) NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
MX375524B (es) Anticuerpos anti-axl.
EP3630169A4 (en) NKG2D, CD16, AND TUMOR-ASSOCIATED PROTEIN
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EA202091567A1 (ru) Химерные белки мти
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
NZ761611A (en) Single-chain trail-receptor agonist proteins
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
PL410572A1 (pl) Aptamer DNA rozpoznający ludzkie białko PCNA oraz jego zastosowanie
TH1701003441A (th) แอนติ-ไมโอสแตตินแอนติบอดี, โพลีเปปไทด์ที่ประกอบด้วยบริเวณแวเรียน Fc และวิธีการของการใช้
EA202090582A2 (ru) ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ